Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 01:25PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.94 Insider Own2.68% Shs Outstand69.91M Perf Week-12.47%
Market Cap222.97M Forward P/E- EPS next Y-0.71 Insider Trans0.00% Shs Float68.66M Perf Month19.25%
Income-65.13M PEG- EPS next Q-0.25 Inst Own77.24% Short Float3.49% Perf Quarter-1.25%
Sales74.23M P/S3.00 EPS this Y39.41% Inst Trans-3.43% Short Ratio4.04 Perf Half Y61.22%
Book/sh1.12 P/B2.81 EPS next Y-5.12% ROA-35.43% Short Interest2.40M Perf Year21.07%
Cash/sh1.22 P/C2.59 EPS next 5Y15.00% ROE-63.45% 52W Range1.45 - 4.91 Perf YTD3.61%
Dividend Est.- P/FCF- EPS past 5Y-39.95% ROI-54.91% 52W High-35.64% Beta2.09
Dividend TTM- Quick Ratio3.63 Sales past 5Y9.69% Gross Margin75.15% 52W Low117.93% ATR (14)0.23
Dividend Ex-Date- Current Ratio3.71 EPS Y/Y TTM-29.20% Oper. Margin-58.06% RSI (14)43.78 Volatility7.16% 7.29%
Employees174 Debt/Eq0.55 Sales Y/Y TTM-36.13% Profit Margin-87.73% Recom1.29 Target Price6.57
Option/ShortYes / Yes LT Debt/Eq0.50 EPS Q/Q51.98% Payout- Rel Volume0.27 Prev Close3.22
Sales Surprise28.30% EPS Surprise11.11% Sales Q/Q31.51% EarningsMay 02 AMC Avg Volume593.27K Price3.16
SMA20-7.83% SMA50-3.11% SMA20021.80% Trades Volume98,320 Change-1.86%
Date Action Analyst Rating Change Price Target Change
Feb-29-24Upgrade The Benchmark Company Hold → Buy
Nov-07-23Downgrade The Benchmark Company Buy → Hold
Aug-07-23Downgrade TD Cowen Outperform → Market Perform $21 → $4
May-09-23Downgrade H.C. Wainwright Buy → Neutral
Mar-31-22Resumed Piper Sandler Overweight $35
Mar-02-22Resumed Cowen Outperform
Apr-12-21Initiated Piper Sandler Overweight $32
Mar-01-21Initiated Stifel Buy $30
Feb-26-21Reiterated H.C. Wainwright Buy $21 → $26
Mar-10-20Initiated The Benchmark Company Buy
May-22-24 04:25PM
May-20-24 04:05PM
May-14-24 06:00AM
May-03-24 11:14AM
04:01AM Loading…
May-02-24 06:06PM
Apr-18-24 04:05PM
Apr-11-24 07:05AM
Feb-29-24 10:40AM
Feb-28-24 06:50PM
04:59PM Loading…
Feb-26-24 04:05PM
Feb-20-24 08:05AM
Feb-14-24 04:05PM
Feb-13-24 04:05PM
Feb-01-24 04:05PM
Jan-08-24 07:03PM
Dec-27-23 08:30AM
Dec-14-23 06:45AM
Dec-13-23 04:06PM
Dec-11-23 07:05AM
Nov-29-23 02:46PM
04:05PM Loading…
Nov-28-23 04:05PM
Nov-14-23 04:05PM
Nov-03-23 09:14AM
Nov-02-23 06:24PM
Oct-31-23 04:05PM
Oct-27-23 03:35PM
Oct-26-23 04:05PM
Oct-19-23 04:05PM
Sep-29-23 07:05AM
Sep-18-23 04:05PM
Sep-16-23 03:02PM
Sep-13-23 01:02AM
Sep-12-23 04:05PM
Sep-11-23 08:21AM
Sep-08-23 04:44PM
Sep-07-23 04:05PM
Aug-24-23 09:29AM
Aug-08-23 06:00PM
Aug-03-23 06:25PM
Jul-31-23 04:05PM
Jul-20-23 05:51PM
Jul-11-23 10:00AM
Jul-10-23 06:09AM
Jul-08-23 08:50PM
Jun-09-23 04:05PM
Jun-08-23 08:18AM
May-24-23 04:05PM
May-10-23 04:05PM
May-08-23 04:05PM
May-04-23 07:05PM
May-01-23 10:01AM
Apr-28-23 07:59AM
Apr-27-23 10:03AM
Apr-20-23 04:05PM
Apr-19-23 04:05PM
Apr-06-23 04:05PM
Apr-04-23 04:05PM
Mar-27-23 07:33AM
Mar-09-23 04:05PM
Feb-27-23 04:05PM
Feb-24-23 10:13AM
Feb-23-23 07:00PM
Feb-22-23 04:05PM
Feb-15-23 04:05PM
Feb-09-23 04:05PM
Feb-07-23 10:07AM
Jan-30-23 05:57AM
Jan-23-23 04:05PM
Dec-20-22 04:05PM
Nov-30-22 08:30AM
Nov-29-22 04:05PM
Nov-16-22 04:05PM
Nov-09-22 06:00AM
Nov-08-22 04:05PM
Nov-07-22 09:55AM
Nov-03-22 05:45PM
Nov-02-22 12:42PM
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dorgan Byron LDirectorNov 15 '23Sale2.1120,00042,168193,461Nov 17 05:14 PM
Norrett KevinChief Operating OfficerSep 11 '23Buy1.729,00015,47998,102Sep 12 04:07 PM
DILLY STEPHEN GEORGESee RemarksSep 08 '23Buy1.7358,479100,952438,878Sep 12 04:06 PM
Fitzgerald Margaret NellSee RemarksSep 08 '23Buy1.7011,83420,06581,420Sep 12 04:06 PM
Ryali SriramChief Financial OfficerSep 08 '23Buy1.7011,65019,856123,441Sep 12 04:07 PM